JP2016526167A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526167A5 JP2016526167A5 JP2016517685A JP2016517685A JP2016526167A5 JP 2016526167 A5 JP2016526167 A5 JP 2016526167A5 JP 2016517685 A JP2016517685 A JP 2016517685A JP 2016517685 A JP2016517685 A JP 2016517685A JP 2016526167 A5 JP2016526167 A5 JP 2016526167A5
- Authority
- JP
- Japan
- Prior art keywords
- peptides
- sample
- alzheimer
- disease
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000090 biomarker Substances 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 238000000034 method Methods 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 21
- 208000024827 Alzheimer disease Diseases 0.000 claims 10
- 210000001124 body fluid Anatomy 0.000 claims 3
- 239000010839 body fluid Substances 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 238000004949 mass spectrometry Methods 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 239000013643 reference control Substances 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1310203.3 | 2013-06-07 | ||
| GBGB1310203.3A GB201310203D0 (en) | 2013-06-07 | 2013-06-07 | Materials and methods relating to Alzheimer's disease |
| PCT/GB2014/051741 WO2014195715A1 (en) | 2013-06-07 | 2014-06-05 | Materials and methods relating to alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016526167A JP2016526167A (ja) | 2016-09-01 |
| JP2016526167A5 true JP2016526167A5 (enExample) | 2018-04-19 |
Family
ID=48875949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517685A Ceased JP2016526167A (ja) | 2013-06-07 | 2014-06-05 | アルツハイマー病に関する物質と方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160123997A1 (enExample) |
| EP (1) | EP3004894A1 (enExample) |
| JP (1) | JP2016526167A (enExample) |
| CA (1) | CA2914559A1 (enExample) |
| GB (1) | GB201310203D0 (enExample) |
| WO (1) | WO2014195715A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201504432D0 (en) * | 2015-03-17 | 2015-04-29 | Electrophoretics Ltd | Materials and methods for diagnosis and treatment of alzheimers disease |
| WO2019012671A1 (ja) * | 2017-07-13 | 2019-01-17 | 株式会社Ｍｃｂｉ | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 |
| WO2020261608A1 (ja) * | 2019-06-28 | 2020-12-30 | 株式会社島津製作所 | アミロイドβの脳内蓄積状態評価方法及び評価装置 |
| US20220260559A1 (en) * | 2020-11-04 | 2022-08-18 | Seer, Inc. | Biomarkers for diagnosing alzheimer's disease |
| US20250191768A1 (en) * | 2020-11-10 | 2025-06-12 | Mcbi Inc. | Combination of biomarkers, and method for detecting cognitive dysfunction or risk thereof by using said combination |
| CN115066615A (zh) * | 2020-12-28 | 2022-09-16 | 株式会社Mcbi | 判定辅助信息生成方法、判定辅助信息生成系统以及信息处理装置 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| EP0533838B1 (en) | 1990-06-11 | 1997-12-03 | NeXstar Pharmaceuticals, Inc. | Nucleic acid ligands |
| DE60239962D1 (de) | 2001-08-14 | 2011-06-16 | Harvard College | Absolute quantifizierung von proteinen und modifizierten formen davon mittels mehrstufiger massenspektrometrie |
| US20030100016A1 (en) * | 2001-11-23 | 2003-05-29 | George Jackowski | Complement C3 precursor biopolymer markers predictive of Alzheimers disease |
| DE10158180A1 (de) * | 2001-11-28 | 2003-09-11 | Biovision Ag | Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung |
| GB0421639D0 (en) * | 2004-09-29 | 2004-10-27 | Proteome Sciences Plc | Methods and compositions relating to alzheimer's disease |
| US7575876B2 (en) * | 2005-10-27 | 2009-08-18 | The University Of Washington | Biomarkers for neurodegenerative disorders |
| EP2044443B1 (en) * | 2006-07-03 | 2011-01-12 | The Johns Hopkins University | Peptide antibody depletion and its application to mass spectrometry sample preparation |
| WO2008021290A2 (en) * | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| AU2007322252A1 (en) * | 2006-11-01 | 2008-05-29 | George Mason Intellectual Properties, Inc. | Biomarkers for neurological conditions |
| GB0704764D0 (en) | 2007-03-12 | 2007-04-18 | Electrophoretics Ltd | Isobarically labelled reagents and methods of their use |
| ES2453106T3 (es) * | 2009-01-26 | 2014-04-04 | Electrophoretics Limited | Métodos de diagnóstico y pronóstico en relación con la enfermedad de Alzheimer |
| JP6012923B2 (ja) * | 2010-12-22 | 2016-10-25 | 株式会社Ｍｃｂｉ | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 |
-
2013
- 2013-06-07 GB GBGB1310203.3A patent/GB201310203D0/en not_active Ceased
-
2014
- 2014-06-05 EP EP14734539.1A patent/EP3004894A1/en not_active Withdrawn
- 2014-06-05 JP JP2016517685A patent/JP2016526167A/ja not_active Ceased
- 2014-06-05 CA CA2914559A patent/CA2914559A1/en not_active Abandoned
- 2014-06-05 US US14/896,388 patent/US20160123997A1/en not_active Abandoned
- 2014-06-05 WO PCT/GB2014/051741 patent/WO2014195715A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526167A5 (enExample) | ||
| JP2016105097A5 (enExample) | ||
| JP2018500004A5 (enExample) | ||
| WO2007117444A3 (en) | Protein detection by aptamers | |
| MY171913A (en) | Methods for determining ligand binding to a target protein using a thermal shift assay | |
| EA200971114A1 (ru) | Определение антигенов, расположенных на эритроцитах, и антиэритроцитарных антител | |
| JP2017524130A5 (enExample) | ||
| JP2016520192A5 (enExample) | ||
| JP2018507254A5 (enExample) | ||
| JP2017508144A5 (enExample) | ||
| RU2019143570A (ru) | Диагностика периодонтита на основании hgf и mmp-8 в слюне | |
| WO2011109112A3 (en) | Method of detecting tau protein and tau fragments in serum | |
| BR112014018204A8 (pt) | Método de diagnóstico de distúrbio de células beta pancreáticas em um indivíduo | |
| HK1254818A1 (zh) | 抗原肽及其用於诊断和治疗自闭症的用途 | |
| JP2016519767A5 (enExample) | ||
| JP2014524583A5 (enExample) | ||
| WO2015006657A3 (en) | Method for the diagnosis and prognosis of cancer | |
| JP2020530120A5 (enExample) | ||
| WO2014151079A3 (en) | Ratio based biomarkers and methods of use thereof for the detection and prognosis of cancer | |
| WO2016143805A1 (ja) | 膀胱がんの検出方法 | |
| JP2018520366A5 (enExample) | ||
| CA2837522A1 (en) | Biomarkers for autoimmune liver diseases and uses thereof | |
| JP2018536152A5 (enExample) | ||
| JP2015503106A5 (enExample) | ||
| JP2017538927A5 (enExample) |